Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is no consensus on the treatment of patients with recurrent infections and isolated immunoglobulin G (IgG)-subclass deficiency and/or selective antipolysaccharide antibody deficiency. Therefore, the Dutch Inter University Working Party will start a study in which the treatment with antibiotics is compared with intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

NCT00168025

Agammaglobulinemia IgG Deficiency Common Variable Immunodeficiency

COMPLETED PHASE3

Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study

NCT01287689

Primary Immunodeficiency (PID) Secondary Immunodeficiency (SID) Neurological Autoimmune Disease

COMPLETED

IVIG vs SCIG in CIDP

NCT05584631

CIDP Immunoglobulin Deficiency Chronic Inflammatory Demyelinating Polyneuropathy

RECRUITING PHASE1

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

NCT00322556

Agammaglobulinemia IgG Deficiency Common Variable Immunodeficiency

COMPLETED PHASE3

Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients

NCT00138697

Hypogammaglobulinemia

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is no consensus on the treatment of patients with recurrent infections and isolated IgG-subclass deficiency and/or selective antipolysaccharide antibody deficiency. At present, there are no robust criteria to predict which patient will or will not respond adequately to antibiotic treatment or to IVIG. Furthermore, it is unknown whether IVIG treatment improves the quality of life in these patients. Therefore, the Dutch InterUniversity Working Party intends to start a study in this patient group. In this study, treatment for a year with antibiotics will be compared with a year intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.

The patient will visit the clinic every 3 months during which laboratory tests and physiological measurements will be performed. Moreover the occurrence of infections and fever, the use of antibiotics, hospital admissions, and quality of life will be documented.

The study should result in a national harmonization in the treatment of this patient group. To this end, the results of the study will be used to compile a treatment protocol for this group of patients in the Netherlands and if applicable also in other countries worldwide.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IgG Deficiency Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antibiotics

A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months.

Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given.

Group Type OTHER

intravenous immunoglobulins

Intervention Type DRUG

* Adults: 600 mg/kg bodyweight every 3 weeks
* Children: 800 mg/kg bodyweight every 3 week

antibiotics

Intervention Type DRUG

* Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.
* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.

intravenous immunoglobulins

B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months.

Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given.

Group Type OTHER

intravenous immunoglobulins

Intervention Type DRUG

* Adults: 600 mg/kg bodyweight every 3 weeks
* Children: 800 mg/kg bodyweight every 3 week

antibiotics

Intervention Type DRUG

* Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.
* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intravenous immunoglobulins

* Adults: 600 mg/kg bodyweight every 3 weeks
* Children: 800 mg/kg bodyweight every 3 week

Intervention Type DRUG

antibiotics

* Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.
* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nanogam co-trimoxazol if not lorated: azitromycine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* IgG subclass deficiency and/or (selective) antipolysaccharide antibody deficiency
* At least 2 physician documented infections before the start of the current treatment or in the last 6 months for newly diagnosed patients.
* Total serum IgG \> 4 g/l
* ≥ 5 years of age
* Informed consent

Exclusion Criteria

* Treatment with any other investigational drug within 7 days prior to study entry, or previous enrolment in this study
* Allergic reactions against human plasma/plasma products, or co-trimoxazole
* An ongoing progressive terminal disease
* Pregnancy or lactation
* History of (transient) cerebrovascular accident or coronary insufficiency
* Renal insufficiency (plasma creatinin \> 115 µmol/L; or creatinin clearance \<20 ml/min)
* An ongoing active disease causing general symptoms e.g. chronic active hepatitis or persistent enterovirus infection with ongoing systemic complaints
* Detectable anti-IgA antibodies
* Active systemic lupus erythematosus (SLE)
* Glucose-6-phosphate hydrogenase deficiency

Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No